UCB SA recently presented positive phase 3 clinical trial data in CDKL5 deficiency disorder (CDD) at the American Epilepsy Society Congress. The results highlight progress in addressing the significant unmet needs in CDD, a rare developmental and epileptic encephalopathy characterized by drug-resistant seizures and complex neurodevelopmental challenges. The data was shared with the scientific community and underscores UCB SA's continued commitment to advancing treatment options for patients and families affected by CDD.